Minnesota and 17 other states will receive a total of 2.3 million dollars from drug maker Endo International, which officials say squashed competition on a pain-relief medication to treat complications of shingles. Attorney General Keith Ellison says Endo is prohibited from paying manufacturers of generic drugs to delay research-and-development, manufacturing or marketing of alternatives to Endo’s brand-name drugs. Ellison says Endo forced consumers to pay inflated prices for a much-needed drug (Lidoderm).